A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BE...
Main Authors: | Yundong He, Ting Wei, Zhenqing Ye, Jacob J. Orme, Dong Lin, Haoyue Sheng, Ladan Fazli, R. Jeffrey Karnes, Rafael Jimenez, Liguo Wang, Liewei Wang, Martin E. Gleave, Yuzhuo Wang, Lei Shi, Haojie Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-03-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-21860-7 |
Similar Items
-
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
by: Qiuhui Li, et al.
Published: (2018-09-01) -
An update on enzalutamide in the treatment of prostate cancer
by: Axel S. Merseburger, et al.
Published: (2015-02-01) -
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
by: Giorgia Gurioli, et al.
Published: (2020-09-01) -
Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy.
by: Manish Kohli, et al.
Published: (2015-01-01) -
Elucidation of AR impact on the paternally expressed Gene 10 (PEG10) in Enzalutamide-resistant prostate cancer
by: Kim, Soojin
Published: (2016)